SG155177A1 - Human monoclonal antibodies against human il-4 - Google Patents

Human monoclonal antibodies against human il-4

Info

Publication number
SG155177A1
SG155177A1 SG200905152-5A SG2009051525A SG155177A1 SG 155177 A1 SG155177 A1 SG 155177A1 SG 2009051525 A SG2009051525 A SG 2009051525A SG 155177 A1 SG155177 A1 SG 155177A1
Authority
SG
Singapore
Prior art keywords
human
monoclonal antibodies
antibodies against
human monoclonal
against human
Prior art date
Application number
SG200905152-5A
Other languages
English (en)
Inventor
Herrera Jose M Carballido
Vries Jan E De
Christoph Schwaerzler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG155177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417303A external-priority patent/GB0417303D0/en
Priority claimed from GB0417306A external-priority patent/GB0417306D0/en
Priority claimed from GB0417301A external-priority patent/GB0417301D0/en
Priority claimed from GB0417304A external-priority patent/GB0417304D0/en
Priority claimed from GB0417305A external-priority patent/GB0417305D0/en
Priority claimed from GB0417302A external-priority patent/GB0417302D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG155177A1 publication Critical patent/SG155177A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200905152-5A 2004-08-03 2005-08-02 Human monoclonal antibodies against human il-4 SG155177A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0417303A GB0417303D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417306A GB0417306D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417301A GB0417301D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417304A GB0417304D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417305A GB0417305D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417302A GB0417302D0 (en) 2004-08-03 2004-08-03 Organic compounds

Publications (1)

Publication Number Publication Date
SG155177A1 true SG155177A1 (en) 2009-09-30

Family

ID=35457817

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200905152-5A SG155177A1 (en) 2004-08-03 2005-08-02 Human monoclonal antibodies against human il-4

Country Status (29)

Country Link
US (2) US7740843B2 (el)
EP (2) EP2327726A3 (el)
JP (1) JP4808712B2 (el)
KR (1) KR101245996B1 (el)
CN (1) CN101001877B (el)
AR (1) AR050044A1 (el)
AU (1) AU2005268932B2 (el)
BR (1) BRPI0514124B8 (el)
CA (1) CA2574289C (el)
CY (1) CY1115524T1 (el)
DK (1) DK1817343T3 (el)
EC (1) ECSP077222A (el)
ES (1) ES2504415T3 (el)
HK (1) HK1109158A1 (el)
HR (1) HRP20140888T1 (el)
IL (1) IL180789A (el)
MA (1) MA28981B1 (el)
MX (1) MX2007001342A (el)
MY (1) MY141851A (el)
NO (1) NO20070854L (el)
NZ (1) NZ552637A (el)
PE (1) PE20060560A1 (el)
PL (1) PL1817343T3 (el)
PT (1) PT1817343E (el)
SG (1) SG155177A1 (el)
SI (1) SI1817343T1 (el)
TN (1) TNSN07036A1 (el)
TW (1) TWI356828B (el)
WO (1) WO2006013087A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104677A2 (en) * 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2670776B1 (en) 2011-02-04 2018-11-21 F. Hoffmann-La Roche AG Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
EP4306544A3 (en) 2014-05-06 2024-03-20 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
EP3454878A4 (en) 2016-05-10 2020-07-29 Hennepin Healthcare Research Institute CYTOKINE IMMUNOMODULATORS AND SIGNALING METHODS
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业（上海）股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
WO2019018441A1 (en) * 2017-07-17 2019-01-24 Massachusetts Institute Of Technology ATLAS OF HEAVY AND ILLUMINATED HEAVY BARRIER TISSUE CELLS
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
BR112021018627A2 (pt) 2019-03-21 2021-11-23 Regeneron Pharma Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
CN117327181A (zh) * 2020-06-22 2024-01-02 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
CN118388645A (zh) * 2024-05-17 2024-07-26 康立泰生物医药(青岛)有限公司 一种抗人白介素4抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH03500050A (ja) 1988-02-02 1991-01-10 シェリング・バイオテック・コーポレーション 免疫グロブリンｅの応答を減少させる方法
PT96230B (pt) * 1989-12-20 1998-06-30 Schering Corp Processo para a producao de um polipeptideo e anticorpos antagonistas da interleuquina-4 humana
WO1993017106A1 (en) * 1992-02-19 1993-09-02 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
CZ283488B6 (cs) 1992-08-20 1998-04-15 Schering Corporation Farmaceutický prostředek obsahující IL-4 a/nebo IL-10 nebo protilátky proti IL-4 a IL-10, způsob jeho výroby a jeho použití
BR9407575A (pt) * 1993-09-07 1996-07-16 Smithkline Beecham Corp Recombinaçao il4 de anticorpos uteis no tratamento de desordens do il4
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
ES2373947T3 (es) 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

Also Published As

Publication number Publication date
EP1817343B1 (en) 2014-06-25
CA2574289C (en) 2014-09-16
WO2006013087A8 (en) 2007-03-01
AU2005268932A1 (en) 2006-02-09
BRPI0514124B1 (pt) 2017-01-31
DK1817343T3 (da) 2014-09-15
AR050044A1 (es) 2006-09-20
EP2327726A3 (en) 2012-07-11
TWI356828B (en) 2012-01-21
AU2005268932B2 (en) 2009-06-25
US20080241160A1 (en) 2008-10-02
EP2327726A2 (en) 2011-06-01
KR101245996B1 (ko) 2013-03-20
BRPI0514124A (pt) 2008-05-27
CA2574289A1 (en) 2006-02-09
CY1115524T1 (el) 2017-01-04
SI1817343T1 (sl) 2014-09-30
TW200617024A (en) 2006-06-01
CN101001877B (zh) 2012-09-26
MA28981B1 (fr) 2007-11-01
JP2008507985A (ja) 2008-03-21
HK1109158A1 (en) 2008-05-30
TNSN07036A1 (en) 2008-06-02
CN101001877A (zh) 2007-07-18
PE20060560A1 (es) 2006-06-27
ES2504415T3 (es) 2014-10-08
ECSP077222A (es) 2007-03-29
NZ552637A (en) 2010-02-26
PT1817343E (pt) 2014-09-09
HRP20140888T1 (hr) 2014-10-24
IL180789A0 (en) 2007-06-03
EP1817343A1 (en) 2007-08-15
US7740843B2 (en) 2010-06-22
PL1817343T3 (pl) 2014-11-28
JP4808712B2 (ja) 2011-11-02
US20100254993A1 (en) 2010-10-07
IL180789A (en) 2017-01-31
MX2007001342A (es) 2007-04-02
MY141851A (en) 2010-07-16
WO2006013087A1 (en) 2006-02-09
BRPI0514124B8 (pt) 2021-05-25
KR20070047299A (ko) 2007-05-04
NO20070854L (no) 2007-04-24

Similar Documents

Publication Publication Date Title
SG155177A1 (en) Human monoclonal antibodies against human il-4
IL291162A (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
IL189528A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
SI1976886T1 (sl) Sredstva in postopki za zdravljenje tumorskih bolezni
ZA200603174B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases
SG135176A1 (en) Modified human four helical bundle polypeptides and their uses
SG165353A1 (en) Improved human interferon molecules and their uses
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602005006758D1 (de) Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
IS7348A (is) N-pýrasínýl-fenýlsúlfónamíð og notkun þeirra til að meðhöndla flakkboðatengda sjúkdóma
NZ599875A (en) Human il-23 antigen binding proteins
TW200612918A (en) Lonidamine analogs
HK1109062A1 (en) Compositions and methods of use for treatment of mammalian diseases
EP1560593A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
HK1154904A1 (zh) 天然 抗體及其抑制劑
WO2004005540A3 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen
GB0405482D0 (en) Materials and methods relating to the treatment of glioblastomas
EP1969008A4 (en) ANTIBODIES TO INTERLEUKIN-22 BINDING PROTEIN AND ITS APPLICATIONS IN THE TREATMENT OF METABOLISM DISORDERS
ZA200802541B (en) Human antibodies against IL13 and therapeutic uses
EP1807108A4 (en) METHOD FOR TREATING AND PREVENTING DISEASES OF BIOLOGICAL LINES
IL165429A0 (en) CD16A binding proteins and use for the treatment of immune disorders